GlassScriptPhysician profile
Alyssa Rosso
NPI 1508477001
$3,189.99
in general payments reported to CMS, 2019-2025
23 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $1,354 · 2023: $674 · 2024: $235 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $666.98 | 2021-2025 | Slynd |
| Abbvie INC. | $568.78 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $273.08 | 2021-2025 | |
| Galderma Laboratories, L.P. | $203.70 | 2023-2025 | Dysport |
| Agile Therapeutics, INC. | $156.27 | 2021-2023 | Twirla |
| Merz North America, INC. | $145.12 | 2024-2025 | |
| Evofem Biosciences, INC. | $140.82 | 2021-2022 | |
| Pfizer INC. | $139.08 | 2021-2025 | |
| Organon LLC | $127.43 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $103.18 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Takeda Pharmaceuticals U.S.A., INC. | $87.03 | 2022 | |
| Merck Sharp & Dohme LLC | $80.63 | 2021-2024 | Gardasil 9, Gardasil |
| Therapeuticsmd, INC. | $71.37 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.85 | 2022-2024 | |
| Myriad Women'S Health, INC. | $68.80 | 2023 | Myrisk |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $62.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Avion Pharmaceuticals | $58.27 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $54.70 | 2024-2025 | Gemtesa |
| Myovant Sciences INC. | $37.53 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $27.78 | 2021 | |
| Urovant Sciences INC | $17.52 | 2022 | |
| Millicent US INC | $16.51 | 2025 | Intrarosa, Femlyv |
| Medline Industries LP | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Rosso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.